VIC Tech forms and builds life science companies based on novel technologies that will improve lives. New therapeutics, medical devices, and diagnostics that solve real-world problems provide the intellectual property foundation for start-ups with high impact and investment return potential. We evaluate over 1,000 technologies annually from research institutions around the world, of which only a tiny fraction is selected as the basis for new companies.
VIC’s Opportunity Assessment (OA) team rigorously vets the selected technologies (see: Opportunity Assessment: How To Vet So Much Tech). If the technology passes through this highly selective process, that technology moves forward in the company creation continuum. At every step, questions related to unmet clinical needs, historical perspectives for other tried solutions, novelty and innovation in specific areas of medicine, potential medical impact, known and likely clinical applications, and – more importantly – clinical market size are brought to the surface.
The MAB also identifies specific technologies within its areas of expertise that “should” exist but don’t. In this case, where a technological advancement is needed for a clear medical need, the medical board determines distinct strategies to meet those needs and guides the opportunity assessment team in their search. Finally, the MAB works with VIC’s affiliated incubator, VIC Foundry, to conceive and develop those new technologies from scratch. These undertakings are aimed at predicting the future by creating it..
Innovation in medicine is essential to meet changing patients’ needs. For their success, collaborations between inventors, scientists, physicians, patient advocates, entrepreneurs, and public-private partnerships are crucial. Start-ups are critical for inventions to become innovations, but most of them fail. Although several factors contribute to their lack of success, the primary cause is the absence of a substantial market for said invention.
Through the MAB, VIC gets formal advice, focused input on product development and market size, rapid access to key opinion leaders, and real-time insights from a diversified field of experts that would have been difficult or impossible to source in an informal capacity. Investors in one of the VIC portfolio companies can rest assured that we make our decisions by accessing the best medical knowledge available.
To learn more about the VIC MAB please visit victech.com/mab
------
References:
1. https://fortune.com/2014/09/25/why-startups-fail-according-to-their-founders/